कंपनी का अवलोकन
LifeVantage Corporation operates within the consumer defensive sector, specifically focusing on the packaged foods industry, where it specializes in the identification, research, development, formulation, and global sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management products, pre and pro-biotics, and skin and hair care solutions. The company's primary product offering includes Protandim, a prominent dietary supplement, which serves as the cornerstone of its international business operations. In terms of scale, the enterprise possesses a market capitalization of $51.48M and generates an annual revenue of $210.05M over the trailing twelve months, employing a workforce of 232 individuals to execute its strategic initiatives. These financial metrics indicate that LifeVantage Corporation functions as a mid-cap entity within the nutraceutical landscape, possessing a revenue base that allows for significant operational reach despite a relatively modest employee count, suggesting a potentially capital-efficient or highly specialized business model typical of the niche packaged foods segment.
वित्तीय स्वास्थ्य
The company reported a revenue of $210.05M for the trailing twelve months, accompanied by a net income of $7.86M and an EBITDA of $11.77M, revealing a substantial gap between total revenue and bottom-line profit that highlights a significant cost structure involving operating expenses, taxes, and interest obligations. While the revenue stream remains robust, the net income figure demonstrates that the company retains approximately 3.7% of its sales as profit, indicating a need to manage overheads effectively to convert gross earnings into shareholder value. The free cash flow stands at -$454,500, which signifies a temporary outflow of cash that may reflect heavy capital expenditures or working capital requirements, thereby limiting immediate financial flexibility for dividends or aggressive debt repayment without external financing. Analyzing the margins, the gross margin is exceptionally high at 78.7%, reflecting the premium pricing power or low direct production costs associated with dietary supplements, whereas the operating margin is a mere 0.5% and the profit margin is 3.7%, indicating that operating expenses consume nearly all of the gross profit. Regarding liquidity and leverage, the company holds $10.18M in cash against $10.69M in debt, resulting in a debt-to-equity ratio of 32.41, which suggests a highly leveraged balance sheet where equity is minimal relative to liabilities. The current ratio of 2.03 indicates a conservative short-term liquidity position, as the company holds more than double the current assets required to cover its current liabilities, providing a buffer against immediate financial obligations. Return on Equity is reported at 25.0% while Return on Assets is 8.5%, metrics that reveal management is generating high returns on the minimal equity invested, though the low ROA reflects the impact of the company's high asset base and significant debt load on overall profitability efficiency.
मूल्यांकन आकलन
LifeVantage Corporation trades with a trailing P/E ratio of 6.70 and a forward P/E of 6.55, where the slight decrease in the forward multiple implies that the market expects a modest improvement in earnings trajectory relative to the current historical performance. The price-to-book ratio is recorded at 1.56, suggesting that the market values the company at a slight premium of 56% over its book value, which may reflect intangible assets like brand equity in the nutraceutical sector that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.25 and an EV/EBITDA of 4.41, figures that collectively suggest the stock is priced at a discount relative to sales and earnings, potentially indicating undervaluation or concerns regarding future cash generation capabilities. The stock's price range over the past year has oscillated between a low of $3.90 and a high of $15.37, providing a clear context for assessing current market positioning relative to historical volatility. The beta value is 0.39, which indicates that the stock exhibits low price volatility and moves with significantly less sensitivity than the broader market, making it an asset with defensive characteristics that may appeal to risk-averse investors during periods of market turbulence.
Growth & Income
The financial data indicates a revenue growth rate of -27.8% year-over-year and an earnings growth rate of -89.5% year-over-year, demonstrating that earnings are contracting at a much faster pace than revenue, which implies a deepening profitability crisis or a sharp decline in margin efficiency driven by the negative earnings growth figure. The company offers a dividend yield of 4.5% with a payout ratio of 29.2%, where the relatively low payout ratio suggests that the dividend is currently funded from accumulated cash rather than current earnings, as the negative earnings growth makes the sustainability of this payout dependent on maintaining cash reserves. Given the negative earnings growth, the company is effectively forced to rely on its cash hoard rather than reinvesting organic earnings into growth, as the current profit structure does not support a traditional growth dividend model. Overall, the growth and income profile presents a complex picture of a company with a high dividend yield supported by strong gross margins but facing severe year-over-year contraction in both top-line revenue and bottom-line earnings, creating a tension between current income generation and future growth potential.